| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| Other Sizes |
| Targets |
5-Bromo-2-methoxypyridine is used as a ligand for the central nicotinic acetylcholine receptor. Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels that mediate fast synaptic transmission in the central and peripheral nervous systems. They are targets for the treatment of various neurological and psychiatric disorders including Alzheimer's disease, schizophrenia, and addiction. The compound's pyridine core provides a scaffold for the development of nAChR ligands. The bromine atom allows for further functionalization through cross-coupling reactions to introduce various substituents that can modulate receptor affinity and selectivity. The methoxy group can influence the compound's electronic properties and lipophilicity, potentially affecting its interactions with the receptor. The compound serves as a building block for the synthesis of nAChR ligands and other biologically active molecules targeting the central nervous system.
|
|---|---|
| ln Vitro |
In vitro, 5-bromo-2-methoxypyridine is used as a ligand for the central nicotinic acetylcholine receptor. It is a biochemical compound that may be utilized as a biomaterial or organic/chemical reagent for biomedical research. In medicinal chemistry, it serves as a building block for the synthesis of nAChR ligands and other CNS-targeting drug candidates. Its bromine atom allows for cross-coupling reactions such as Suzuki, Heck, and Buchwald-Hartwig couplings, enabling the introduction of various substituents. The methoxy group can be converted to other functional groups through demethylation and subsequent transformations. In organic synthesis, it is used as a versatile building block for creating complex molecules efficiently.
|
| Enzyme Assay |
Cell-free assays for 5-bromo-2-methoxypyridine are focused on its use as a chemical reagent. Standard protocols for cross-coupling reactions involving the compound include Suzuki coupling with boronic acids, Heck coupling with alkenes, and Buchwald-Hartwig amination with amines. These reactions are typically carried out with a palladium catalyst, a base, and an appropriate solvent at elevated temperatures under an inert atmosphere. The reaction progress is monitored by TLC or HPLC, and the products are purified by column chromatography. The compound's reactivity can be studied using various analytical techniques including NMR spectroscopy, mass spectrometry, and HPLC. Its use as a building block for pharmaceutical synthesis involves standard organic synthesis procedures.
|
| Cell Assay |
Cellular assays are not commonly performed with 5-bromo-2-methoxypyridine itself, as it is primarily a chemical intermediate rather than a bioactive compound. However, its derivatives, such as nAChR ligands, are evaluated in cell-based systems. For nAChR ligands, cell lines expressing nAChRs are treated with the derivatives, and receptor binding, ion flux, or other signaling endpoints are measured. The parent compound itself is not used as a test article in cell-based experiments due to its primary role as a synthetic building block.
|
| Animal Protocol |
Animal studies are not conducted with the parent compound 5-bromo-2-methoxypyridine. Its derivatives, such as nAChR ligands, are evaluated in animal models of neurological and psychiatric disorders. The parent compound itself is not administered to animals, as it is a synthetic intermediate. Toxicity and pharmacological profiles for the parent compound are inferred from related halogenated pyridine derivatives.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 5-bromo-2-methoxypyridine are not available, as the compound is primarily a chemical intermediate rather than a drug candidate. With a molecular weight of 188.02 g/mol and appearing as a light yellow liquid, the compound would be expected to have moderate lipophilicity and membrane permeability if administered. However, comprehensive pharmacokinetic studies including absorption, distribution, metabolism, and excretion have not been performed, as the compound is not intended for therapeutic use. For research purposes, the compound is typically handled as a neat chemical and not administered to living organisms for pharmacokinetic profiling.
|
| Additional Infomation |
5-Bromo-2-methoxypyridine is a research chemical, not an approved drug. It has no clinical trial or marketing approval status for therapeutic use. The compound is a halogenated heterocyclic aromatic compound characterized by a bromine atom at the 5-position and a methoxy group at the 2-position on a pyridine ring. It is used as a ligand for the central nicotinic acetylcholine receptor. It is a biochemical compound that may be utilized as a biomaterial or organic/chemical reagent for biomedical research. The compound has a molecular weight of 188.02 g/mol, appears as a light yellow liquid, and has a boiling point of 80 °C at 12 mmHg and a density of 1.453 g/mL at 25 °C.
|
| Molecular Formula |
C6H6BRNO
|
|---|---|
| Molecular Weight |
188.02
|
| Exact Mass |
186.963
|
| CAS # |
13472-85-0
|
| PubChem CID |
2734895
|
| Appearance |
Colorless to light yellow liquid（Density：1.453 g/cm3）
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
197.0±20.0 °C at 760 mmHg
|
| Melting Point |
80ºC (12 mmHg)
|
| Flash Point |
72.9±21.8 °C
|
| Vapour Pressure |
0.5±0.4 mmHg at 25°C
|
| Index of Refraction |
1.543
|
| LogP |
2.61
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
9
|
| Complexity |
89.1
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1=CN=C(C=C1)OC
|
| InChi Key |
XADICJHFELMBGX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H6BrNO/c1-9-6-3-2-5(7)4-8-6/h2-4H,1H3
|
| Chemical Name |
5-bromo-2-methoxypyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3186 mL | 26.5929 mL | 53.1858 mL | |
| 5 mM | 1.0637 mL | 5.3186 mL | 10.6372 mL | |
| 10 mM | 0.5319 mL | 2.6593 mL | 5.3186 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
